Citigroup Rates Apogee Therapeutics (APGE) hold

Citigroup shifted its rating on Apogee Therapeutics, Inc. to a neutral stance while setting a target price, a 1.75% upside from the current price.

By EarningsIQ Research Desk · Published Jun 23, 2026, 11:01 AM EDT · Updated Jun 26, 2026, 10:02 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Citigroup rated Apogee Therapeutics, Inc. ($APGE) "hold" with a $135 price target on June 23, 2026.

APGE Apogee Therapeutics, Inc.

$132.65 +75.05% year to date

Daily close · Jun 22, 2026

Key Points

Citigroup lowered its rating on Apogee Therapeutics, Inc. (APGE:NGM) to a neutral stance on June 23, 2026, while setting a price target of $135.
Citigroup's $135 price target implies 1.75% upside from Apogee Therapeutics, Inc.'s ($APGE) current $132.68 share price.
The biotechnology company trades near its 52-week high of $135.09, well above its 200-day moving average of $93.12.
A broader group of five analysts currently maintains a consensus hold recommendation with an average price target of $134.62.

Get $APGE trade alerts by text

We text you when insiders, Congress or big funds trade $APGE. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Apogee Therapeutics, Inc. alert may contain errors. Disclosures

Citigroup Adjusts Rating on Apogee Therapeutics

Citigroup updated its outlook on Apogee Therapeutics, Inc. (APGE:NGM) on June 23, 2026, when analyst Geoff Meacham lowered the firm's view on the biotechnology company to a neutral rating. Alongside the rating change, the firm set a price target of $135. The adjustment reflects a fresh look at the company's valuation following a significant run in its share price over recent months.

Analyst rating track record

Citigroup vs. the S&P 500

YTD return -2.20% hypothetical

All-time return +32.45% S&P 500 +29.29%

vs. S&P 500 +3.16% ahead of the index

Hypothetical returns from Citigroup's disclosed trades, not real profit or advice. How we model this.

Stock Performance and Recent Trading

Shares of Apogee Therapeutics traded hands around $132.68, sitting close to the upper end of a 52-week trading range that spans from a low of $35.39 to a peak of $135.09. The equity trades far above its 200-day moving average of $93.12 and just under its 50-day moving average of $134.18. With a market capitalization near $10.22 billion and a beta of 0.33, the stock has shown lower volatility than the broader market while maintaining strong upward momentum through the middle of the year.

12-month forecast

$APGE price target

Apogee Therapeutics, Inc. daily closes and this analyst's $135 target. Not advice.

Wall Street Analyst Coverage and Rating Changes

Wall Street firms have kept a close eye on the biotech stock, with several adjustments following Citigroup's move. On June 23, 2026, Deutsche Bank shifted its rating to a hold while establishing a $135 target. The following day on June 24, 2026, Stifel moved its rating to a hold with a $135 target, up from an earlier target of $133. TD Cowen, Guggenheim, and Mizuho also updated their views on June 24, 2026, with Mizuho moving to a neutral rating and setting a $135 target. Later in the summer, BTIG moved to a neutral rating on August 12, 2026, and Truist Securities maintained a hold rating while lifting its target to $135 on August 13, 2026. Across five analyst opinions, the stock carries a consensus hold rating and an average price target of $134.62.

Pipeline Focus and Corporate Background

Apogee Therapeutics focuses on developing biologic treatments for immunological and inflammatory diseases. Its pipeline includes antibody candidates targeted at conditions like atopic dermatitis, asthma, chronic obstructive pulmonary disease, and eosinophilic esophagitis. The company operates from San Francisco, California, and functions as a subsidiary of AbbVie Inc. as of September 2026.

What to Watch at Apogee Therapeutics, Inc.

Market participants will look toward the company's next earnings report scheduled for November 9, 2026, for further updates on its clinical pipeline and financial position. Investors should also monitor subsequent analyst updates and any further filings from the company to gauge how its drug candidates progress through clinical trials.